Medtronic’s Renal Denervation System Will Get Parallel Treatment From FDA And CMS

The device is one of the first, and perhaps the most high profile, to participate in the budding parallel review program, in which CMS can begin considering a national Medicare coverage policy for a new technology as FDA is reviewing its safety and efficacy for regulatory approval.

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Policy & Regulation

More from Medtech Insight